
341 Children 6–10 yr of age were assessed for eligibility
73 Were excluded
54 Did not meet eligibility criteria
17 Served as back-ups and were not needed
1 Declined to participate
1 Was unable to enroll because of acute illness
268 Were enrolled in part A or B
41 Were enrolled in the safety trial (part A) and received artemether–lumefantrine
231 Were enrolled in the efficacy trial (part B) and received artemether–lumefantrine
5 Did not undergo randomization
4 Served as backups, were not needed, and were reenrolled in part B
1 Met exclusion criteria before randomization
6 Did not undergo randomization
5 Served as backups and were not needed
1 Met exclusion criteria before randomization
36 Underwent randomization
225 Underwent randomization
9 Were assigned to receive L9LS, 150 mg
9 Were assigned to receive L9LS, 300 mg
18 Were assigned to receive placebo
75 Were assigned to receive L9LS, 150 mg
75 Were assigned to receive L9LS, 300 mg
75 Were assigned to receive placebo
9 Were evaluated for safety
9 Were evaluated for safety
18 Were evaluated for safety
75 Were evaluated for safety
75 Were evaluated for safety
75 Were evaluated for safety
1 Was lost to follow-up
1 Withdrew consent
1 Withdrew consent
1 Was lost to follow-up
2 Withdrew consent
9 Completed the trial
9 Completed the trial
18 Completed the trial
73 (97%) Completed the trial
74 (99%) Completed the trial
72 (96%) Completed the trial
75 Were evaluated for efficacy
75 Were evaluated for efficacy
75 Were evaluated for efficacy